PAUL ANDREA (General Counsel) sold 1.2% of their position (13.23K shares) of ZENTALIS PHARMACEUTICALS, INC. on the open market
Open‑market sale worth $22.6K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 2/5/2025ACC: 0001725160-25-000040
Officer· General Counsel
Since Aug 2022
+1.05M
Net shares
Net buyer
$22.6K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
1.06M acquired · 13.23K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+934.04K
Price / share
—
Trade value
—
% of position
622.8%
2/3/2025
149.97K→1.08M
Common Stock
Direct
Shares
−13.23K
Price / share
$1.71
Trade value
$22.64K
% of position
1.2%
2/3/2025
1.08M→1.07M
Total
Net shares
+920.81K
Net value
-$22.64K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 2/3/2025 | A · Award | +934.04K | — | — | 622.8% | 149.97K | 1.08M |
| Common Stock Direct | 2/3/2025 | S · Sale | −13.23K | $1.71 | $22.64K | 1.2% | 1.08M | 1.07M |
| Total | +920.81K | -$22.64K | ||||||
Derivative Transactions1
Stock Option (Right to Buy)
Direct
Converts to
Common Stock
124.71K shares
Shares
+124.71K
Strike price
1.68
Held after
124.71K
Exercisable
—
2/3/2025
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Stock124.71K shares | 2/3/2025 | A · Award | +124.71K | 1.68 | — | 124.71K |